Focus: Novanta is a public medical device and diagnostics company specializing in surgical cameras and pumps across gastroenterology, neurology, ophthalmology, and respiratory markets. With $882M in FY2025 revenue and 1,001-5,000 employees, the company operates as a scaled, profitable medical technology provider.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Hot — 68 jobs added in 30d
Net +32 (68 new, 36 removed). Aggressive expansion phase.
Best fit for manufacturing, quality, biomedical engineering, or operations professionals; limited appeal for discovery scientists or clinical development careers.
Core product line driving gastroenterology and ophthalmology revenue.
Help build intelligence for Novanta
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Novanta's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Established platform serving neurology and respiratory indications with recurring revenue potential.
Novanta (NOVT) Margin Compression Challenges High Growth Narrative After FY 2025 Results - simplywall.st
Novanta (NOVT) Margin Compression Challenges High Growth Narrative After FY 2025 Results simplywall.st
8-K Filing: NOVANTA INC (NOVT, NOVTU) (CIK 0001076930) — EX-99.1
EX-99.1
8-K Filing: e.l.f. Beauty, Inc. (ELF) (CIK 0001600033) — 8-K
8-K
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub